Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Splenectomy for solitary splenic metastasis of ovarian cancer

BMC Cancer20044:96

DOI: 10.1186/1471-2407-4-96

Received: 01 July 2004

Accepted: 22 December 2004

Published: 22 December 2004

Abstract

Background

Splenic metastases occur in rare cases with a few case reports of patients in the literature. Generally, splenic metastases mean late dissemination of a disease. Solitary splenic metastases from solid tumors are extremely unusual.

Case presentation

We report a case of a patient with ovarian mucinous cystadenocarcinoma who underwent splenectomy for isolated parenchymal metastasis.

Conclusion

Ovarian epithelial tumors comprised most of isolated splenic metastases from gynecologic tumor. When isolated splenic recurrence is suspected on image studies and serum tumor markers, intraabdominal gross findings should be examined to exclude peritoneal carcinomatosis. If only spleen was under suspicion of recurrence of ovarian cancer, splenectomy may play a therapeutic role.

Background

Splenic metastases from solid tumors occur in late stage of a disease, so those can hardly be an indication for a surgery. Cancers of the ovaries, lung, breast, stomach, skin and colon are known to metastasize to the spleen [1]. Even though recent reports suggest increasing incidence of splenic metastasis from gynecologic tumors [28], the number of the cases that isolated splenic metastasis is fewer than 25 in the literature worldwide. Among them, solitary parenchymal metastasis would comprise the small portion. Fewer than 15 cases of splenic metastasis occur from the ovaries as a primary site, pathology revealed cystadenocarcinoma.

We present a case of mucinous cystadenocarcinoma that recurred in the splenic parenchyma.

Case presentation

A 29-year-old woman was admitted our hospital on August 1999, had been diagnosed as mucinous tumor of borderline malignancy a year ago. She was followed up at a local clinic. On the follow-up study, the patient's CEA level was raised to 43.32 U/L and CT scan showed splenomegaly with cystic lesion. Her past medical history was not significant. She already underwent two surgeries. The first surgery, right salpingo-oophorectomy, was performed at the age of 22 after being diagnosed as dermoid cyst. She was healthy thereafter. Seven years later, left ovarian mass was found on the routine check. At the second surgery, left ovarian mass excision, mucinous tumor of borderline malignancy was diagnosed.

During follow-up after the second surgery, she was referred to our hospital on the suspicion of carcinomatosis peritonei. On the preoperative evaluation (Figure 1), splenic lesion, which had been existed for 2 years, was merely noticed as simple cystic lesion unrelated to the ovarian mass.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-4-96/MediaObjects/12885_2004_Article_186_Fig1_HTML.jpg
Figure 1

Abdomen CT shows 9 × 8 cm-sized multiseptated cystic lesion with inner calcification in the spleen.

To exclude peritoneal carcinomatosis, open laparotomy was perfomed. On opening the abdomen, no abnormal gross findings were found except the splenic lesion, which reported as probable metastatic adenocarcinoma on frozen sections. After splenectomy was carried out, peritoneal washings and multiple biopsies on the omentum, peritoneum, mesentery, and left ovary were performed to rule out possible microscopic peritoneal dissemination. Suspecting the transabdominal metastasis, 100 mg of cisplatin was infused into the peritoneal cavity at the end of the operation; however no intraperitoneal recurrence was confirmed after tissue diagnosis.

Final pathologic examination (Figure 2) showed metastatic mucinous cystadenocarcinoma. Peritoneal washings and multiple biopsies were all negative. The patient was recovered from the surgery without the evidence of sepsis of severe thrombocytosis. The patient received 5 courses of Taxol and Carboplatin as postoperative chemotherapy.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-4-96/MediaObjects/12885_2004_Article_186_Fig2_HTML.jpg
Figure 2

The section reveals papillary hyperplasia of mucinous lining epithelium with stratification and atypism (H&E stain, ×250).

Two years after the surgery, 3 × 3-sized mass on the left ovary, which assumed to be recurrence, was detected. She has been followed up at outpatient department receiving symptomatic treatment and chemotherapy.

Discussion

The frequency of splenic metastasis has been reported 2.3 to 7.1 per cent from autopsy series of cancer patients [911]. Splenic metastases from the ovaries, uterus, uterine cervix, lung, breast, stomach, skin and colon have been reported, and ovarian cancer comprises the three fourth.

Until now, in the literature, splenic capsular metastasis has been reported to occur in the case of far advanced stage of a disease or in the case of more than one organ was already involved in terminal stage and especially in the case of peritoneal metastasis. When one or more organ in the thoracic cavity and abdominal cavity was involved, the rate of splenic metastasis was 43% [12]. But isolated splenic metastasis is rare; only fewer than 25 cases were reported. Some reported hematogenous metastasis to the parenchyma of the spleen [13]. This mean the spleen is the organ of the privilege [11, 14, 15]. It could be explained by hypothesis of the role of the splenic capsule as physical barrier; the lack of afferent lymphatics in the splenic parenchyma, the acute angle of the origin and the tortuosity of the splenic artery, the rhythmic contractile properties of the spleen, and the immune competence and possible antineoplastic nature of the splenic tissue itself [13]. In this case, solitary splenic parenchymal metastasis from ovarian epithelial tumor was made hematogenously without intraabdominal dissemination.

Among cases of the isolated splenic metastasis, the ovarian cancers make up the most. After Minazawa et al [16] firstly performed splenectomy in the splenic metastasis of ovarian cancer patient, splenectomy, as a therapeutic modality of splenic metastasis, was supported by similar articles and studies [17, 18]. Recently, splenectomy was often included in the cytoreductive surgery of the ovarian cancer [2, 3, 19].

CT scanning and measurement of serum tumor markers, especially CA 125, are helpful for detecting the recurrence and the infrequent splenic metastasis.

We proposed that splenectomy be a proper therapeutic modality for an isolated splenic metastasis, especially parenchymal metastasis, from an ovarian cancer. When isolated splenic recurrence is suspected on the CT scanning and serum tumor markers, intraabdominal gross findings should be examined meticulously. If only spleen was under suspicion of recurrence, splenectomy would be a proper therapeutic procedure.

Declarations

Acknowledgement

Written consent for publication of the case was obtained from a relative of a patient.

Authors’ Affiliations

(1)
Department of Surgery, Chonnam University Medical School, Chonnam National University Hospital

References

  1. Marymont JH, Gross S: Patterns of metastatic cancer in the spleen. Am J Clin Pathol. 1963, 40: 58-66.View ArticlePubMedGoogle Scholar
  2. Nicklin JL, Copeland LJ, O'Toole RV, Lewandowski GS, Vaccarello L, Havenar LP: Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol Oncol. 1995, 58: 244-247. 10.1006/gyno.1995.1218.View ArticlePubMedGoogle Scholar
  3. Sonnendecker EW, Guidozzi F, Margolius KA: Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol. 1989, 35: 301-306. 10.1016/0090-8258(89)90068-1.View ArticlePubMedGoogle Scholar
  4. Morris M, Gershenson DM, Burke TW, Wharton JT, Copeland LJ, Rutledge FN: Splenectomy in gynecologic oncology: Indications, complications and technique. Gynecol Oncol. 1991, 43: 118-122. 10.1016/0090-8258(91)90056-B.View ArticlePubMedGoogle Scholar
  5. Farias-Eisner R, Braly P, Berek JS: Solitary recurrent metastasis of epithelial ovarian cancer in the spleen. Gynecol Oncol. 1993, 48: 338-341. 10.1006/gyno.1993.1059.View ArticlePubMedGoogle Scholar
  6. Munkarah AR, Hallum AV, Morris M, Burke TW, Levenback C, Atkinson EN, Wharton JT, Gershenson DM: Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997, 64: 13-17. 10.1006/gyno.1996.4540.View ArticlePubMedGoogle Scholar
  7. Gemignani ML, Chi DS, Gurin CC, Curtin JP, Barakat RR: Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol. 1999, 72: 407-410. 10.1006/gyno.1998.5141.View ArticlePubMedGoogle Scholar
  8. Max LD, Strastny JF, Frable WJ: Solitary splenic metastasis of an adenocarcinoma of the ovaries. Gynecol Obstet Invest. 1996, 42: 214-216.View ArticlePubMedGoogle Scholar
  9. Hirst AE, Bullock WK: Metastastic carcinoma of the spleen. Am J Med Sci. 1952, 223: 414-417.View ArticlePubMedGoogle Scholar
  10. Berge T: Splenic metastases Frequencies and patterns. Acta Pathol Microbiol Scand. 1974, 82: 499-506.Google Scholar
  11. Warren S, Davis AH: Studies on tumor metastasis: The metastases of carcinoma to the spleen. Am J Cancer. 1934, 21: 517-533.View ArticleGoogle Scholar
  12. Harman JW, Dacorso P: Spread of carcinoma to the spleen: Its relation to generalized carcinomatous spread. Arch Pathol. 1948, 45: 179-186.Google Scholar
  13. Lee SS, Morgenstern L, Phillips EH, Hiatt JR, Margulies DR: Splenectomy for splenic metastases: a changing clinical spectrum. Am Surg. 2000, 66: 837-840.PubMedGoogle Scholar
  14. Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 1889, 1: 571-573. 10.1016/S0140-6736(00)49915-0.View ArticleGoogle Scholar
  15. Morgenstern L, Rosenberg J, Geller SA: Tumors of the spleen. World J Surg. 1985, 9: 468-476.View ArticlePubMedGoogle Scholar
  16. Minagawa Y, Kanamori Y, Ishihara H, Morishita K, Kigawa J, Ito T, Maeda K, Saito S: Solitary metastatic ovarian carcinoma of the spleen: A case report. Asia Oceania J Obstet Gynaecol. 1991, 17: 45-48.View ArticlePubMedGoogle Scholar
  17. Glezerman M, Yanai-Inbar I, Charuzi I, Katz M, Glasner M, Piura B: Involvement of the spleen in ovarian adenosquamous carcinoma. Gynecol Oncol. 1988, 30 (1): 143-148. 10.1016/0090-8258(88)90058-3.View ArticlePubMedGoogle Scholar
  18. Carrington BM, Thomas NB, Johnson RJ: Intrasplenic metastases fromcarinoma of the ovary. Clin Radiol. 1990, 41: 418-420.View ArticlePubMedGoogle Scholar
  19. Malfetano JH: Splenectomy for optimal cytoreduction in ovarian cancer. Gynecol Oncol. 1986, 24: 392-394. 10.1016/0090-8258(86)90319-7.View ArticlePubMedGoogle Scholar
  20. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/4/96/prepub

Copyright

© Koh et al; licensee BioMed Central Ltd. 2004

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement